Antonio Abbate

Active 2002–2026

249
Papers
30,014
Citations
102
h-index
234
i10-index

Citations

Citations per year for Antonio Abbate1996: 1 citations1999: 2 citations2001: 1 citations2002: 4 citations2003: 13 citations2004: 19 citations2005: 17 citations2006: 33 citations2007: 46 citations2008: 54 citations2009: 87 citations2010: 101 citations2011: 143 citations2012: 152 citations2013: 170 citations2014: 246 citations2015: 221 citations2016: 176 citations2017: 255 citations2018: 310 citations2019: 884 citations2020: 1,395 citations2021: 1,614 citations2022: 1,463 citations2023: 1,180 citations2024: 1,866 citations2025: 1,131 citations2026: 42 citations1997–1998: no citations, so these years are not shown2000: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,885 citing papers, 21.6% of this breakdownChina: 1,944 citing papers, 14.5% of this breakdownItaly: 950 citing papers, 7.1% of this breakdownUnited Kingdom: 782 citing papers, 5.8% of this breakdownGermany: 677 citing papers, 5.1% of this breakdownCanada: 510 citing papers, 3.8% of this breakdownNetherlands: 432 citing papers, 3.2% of this breakdownFrance: 362 citing papers, 2.7% of this breakdownSpain: 328 citing papers, 2.5% of this breakdownAustralia: 308 citing papers, 2.3% of this breakdownJapan: 296 citing papers, 2.2% of this breakdownSwitzerland: 215 citing papers, 1.6% of this breakdown
0%21.6%Other 27.6%

Fields

  • Medicine65.7%
  • Biochemistry, Genetics and Molecular Biology22.6%
  • Immunology and Microbiology6.5%
  • Neuroscience1.3%
  • Nursing0.7%
  • Engineering0.6%
  • Other2.6%

Topics

  • Inflammasome and immune disorders5.8%
  • Cardiac Fibrosis and Remodeling3.4%
  • Cardiovascular Function and Risk Factors3.3%
  • COVID-19 Clinical Research Studies2.9%
  • Heart Failure Treatment and Management2.2%
  • Pulmonary Hypertension Research and Treatments1.8%
  • Other80.6%

Coauthors

All papers

Open in search
  1. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease

    Authors: , , , , , - Circulation Research 2020 cited by 714

  2. The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases

    Authors: , - Nature Reviews Cardiology 2023 cited by 349

  3. Targeting the NLRP3 inflammasome in cardiovascular diseases

    Authors: , , , , , , , - Pharmacology & Therapeutics 2021 cited by 312

  4. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure

    Authors: , , , , , , , , - Circulation 2019 cited by 636

  5. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19

    Authors: , , , , , , , , , , - Nature reviews. Immunology 2021 cited by 967

  6. The NLRP3 inflammasome in acute myocardial infarction

    Authors: , - Nature Reviews Cardiology 2017 cited by 638

  7. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis

    Authors: , , , , , , , , , , , , , , - New England Journal of Medicine 2020 cited by 334

  8. Interleukin‐1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST‐Segment–Elevation Myocardial Infarction

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American Heart Association 2020 cited by 289

  9. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial

    Authors: , , , , , , , , , - Nature Medicine 2022 cited by 236

  10. Exercise Intolerance in Patients With Heart Failure

    Authors: , , , , , , , , , , - Journal of the American College of Cardiology 2019 cited by 445

  11. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse

    Authors: , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2011 cited by 621

  12. Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury

    Authors: , , , - American Journal of Physiology-Heart and Circulatory Physiology 2018 cited by 370

  13. IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction

    Authors: , , , , , , , , , , , , , , , - Circulation Heart Failure 2018 cited by 206

  14. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , W.H. Wilson Tang, Yair Lev, Preethi William, Arthur L. Eberly, Stephen S. Gottleib, W. Herbert Haught, Gillian Grafton, Joshua Larned, Lokesh Tejwani, Freny Vaghaiwalla Mody, Selim R. Krim, Monique Robinson, James C. Fang, Alexander A. Adler, Adrian C. Bell, Dipanjan Banerjee, Ernesto A. Ruiz Duque, Ahmad Mizyed, John Rommel, Justice Arhinful, Parag Goyal, Michael E. Hall, Scott L. Hummel, Sanjay Shetty, Donald Haas, Juan Vilaro, Tamás Alexy, John M. Herre, J.M. Clark, Andrew P. Ambrosy, Nunzio Gaglianello, Kumudha Ramasubbu, Judith Meadows, Sara Tabtabai, Melody Sherwood, Syed Farhan Hasni, Michael D'Urso, Basharat Muneer, Stephanie H. Dunlap, William C. Davis, Dennis Friedman, Maya Guglin, Andrew D. Ferguson, Antonio Abbate, Frank W. Smart - JAMA 2023 cited by 181

  15. Guidelines for evaluating myocardial cell death

    Authors: , , , , , , , , , , , , , , - American Journal of Physiology-Heart and Circulatory Physiology 2019 cited by 230

  16. Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II–III Systolic Heart Failure

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Cardiovascular Pharmacology 2020 cited by 159

  17. Coronary microvascular obstruction and dysfunction in patients with acute myocardial infarction

    Authors: , , , , , , , , , , , , , - Nature Reviews Cardiology 2023 cited by 143

  18. Neutrophil Extracellular Traps and Cardiovascular Diseases: An Update

    Authors: , , , - Cells 2020 cited by 181

  19. Acute Myocarditis Associated With Desmosomal Gene Variants

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Julia Cadrin‐Tourigny, Rafik Tadros, G Annoni, Emanuela Bonoldi, Claire Toquet, Lara Marteau, Vincent Probst, Jean‐Noël Trochu, Antheia Kissopoulou, Aurelia Grosu, Deni Kukavica, Alessandro Trancuccio, Cristina Gil, Giacomo Tini, Matteo Pedrazzini, Margherita Torchio, Gianfranco Sinagra, Juan R. Gimeno, Davide Paolo Bernasconi, Maria Grazia Valsecchi, Karin Klingel, Eric Adler, Paolo G. Camici, Leslie T. Cooper - JACC Heart Failure 2022 cited by 131

  20. Molecular and Cellular Mechanisms of Action of Cannabidiol

    Authors: , , , , , - Molecules 2023 cited by 128

  21. Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Circulation 2023 cited by 63

  22. Effects of Interleukin-1 Blockade With Anakinra on Aerobic Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction (from the D-HART Pilot Study)

    Authors: , , , , , , , , , , , , - The American Journal of Cardiology 2013 cited by 273

  23. Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure

    Authors: , , , , , , , , , , , , , , , , , , , , , - Circulation Heart Failure 2017 cited by 236

  24. Ischemic Cardiomyopathy and Heart Failure After Acute Myocardial Infarction

    Authors: , , , , , - Current Cardiology Reports 2022 cited by 166